Contact Activation Pathway Function Blocking Antibody AB023
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA) is conducting market research through a Request for Information (RFI) for a Contact Activation Pathway Function Blocking Antibody AB023. This RFI aims to identify qualified offerors capable of providing this specialized antibody. Responses are due June 18, 2026, at 10:00 ET.
Scope of Work
The DHA seeks a Coagulation Factor XI (FXI) Inhibitor AB023 (Xisomab 3G3 / Gruticibart) with specific characteristics:
- Targeting: Shall target specific blood clotting factors without increasing bleeding risk, binding to the "apple 2" domain of FXI to inhibit activation by FXIIa in the "contact pathway." It is designed for use in Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-related thrombosis.
- Hemostasis Preservation: Must preserve natural clotting by not blocking FXI activation by thrombin or the conversion of Factor IX by activated Factor XI (FXIa).
- Supply & Testing: Provide a maximum of 0.5g of AB023 annually. Conduct pharmacokinetics (PK) and pharmacodynamics (PD) testing, showing dose-dependent prolongation of activated partial thromboplastin time (aPTT) without affecting Prothrombin Time (PT). It must be effective in preventing platelet-rich thrombus growth and fibrin accumulation in vascular thrombosis models.
- Validation: Validated using clotting assays for stability, dose, and potency.
Contract & Timeline
- Type: Request for Information (RFI) / Sources Sought (Market Research)
- NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology); Small Business Size Standard 1,000 employees.
- Set-Aside: None specified (market research stage).
- Response Due: June 18, 2026, 10:00 ET.
- Published: June 12, 2026.
Additional Notes
This is an RFI for market research purposes only and does not constitute a solicitation or obligate the Government to award a contract. Responses will not be reimbursed. No subcontracting opportunity is anticipated. Offerors must be registered in SAM.gov.